In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. The American Association of Orthopedic Surgeons estimates that approximately 11% of all injuries—things like fractures, dislocations, and tears to the knees and shoulders--are related to sports, to the tune of 6.6 million such injuries each year. Three-quarters of these patients are under the age of 65. An increase in the number of aging and active people is bound to contribute to the growing number of injuries. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc. for $130 million in a combination of cash and stock, plus earn-outs based on sales thresholds. [See Deal] Indeed, says ArthroCare president Michael Baker, the company has been in discussions with Opus for a year.
ArthroCare Sews Up an Advantage in Sports Medicine
In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc., developer of a novel suturing and anchor system for arthroscopic soft tissue repair. In sports medicine, AthroCare's largest and most established target market (spine and ear, nose & throat are its other major markets), the Opus technology will help ArthroCare increase market penetration.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.